Clinical trials: Blood Plasma Therapy
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
RATIONALE: Questionnaires that measure quality-of-life may improve the health care team's ability to plan supportive care for patients undergoing donor bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281801
- Testing
- psychosocial assessment and care, Quality of Life Assessments
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Case Comprehensive Cancer Center
Lateral Epicondylitis (Tennis Elbow)
Comparison of Platelet Rich Plasma and Alternative Therapies for the Treatment of Tennis Elbow (Lateral Epicondylitis)
"Tennis elbow" is the most common cause of lateral elbow pain, generally caused by either work or sports related repetitive strain.
- Trial name
- IMPROVE (NCT01668953)
- Testing
- Platelet Rich Plasma (PRP) Injection, Whole Blood Injection, Dry Needle Fenestration
- Where
- 2 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- McMaster University
Multiple Myeloma, Plasma Cell Myeloma
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide and lenalidomide, may stimulate the immune system in different ways and…
- Trial name
- NCT01055301
- Testing
- bortezomib, cisplatin, cyclophosphamide
- Where
- 21 sites in United States
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.
- Trial name
- NCT03748953
- Testing
- Ixazomib
- Where
- 10 sites in China
- Volunteers
- 37 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
- Conditions
- Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
- Trial name
- NCT03628612
- Testing
- AUTO CAR T cell therapy
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 500 people
- Sponsor
- Autolus Limited
High Risk Smoldering Multiple Myeloma (HR-SMM)
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of…
- Trial name
- LINKER-SMM2 (NCT07393282)
- Testing
- Linvoseltamab, Daratumumab
- Where
- 27 sites in United States, Japan and 3 more
- Volunteers
- 270 people
- Sponsor
- Regeneron Pharmaceuticals
Esophageal Cancer
The Utility of Circulating Tumour Cells and Plasma microRNA in Esophageal Adenocarcinoma
Circulating microRNA (circ miRNA) and circulating tumor cell (CTC) levels are hypothesized to be associated with response to chemoradiation in patients undergoing treatment for locally advanced esophageal adenocarcinoma.
- Trial name
- NCT02812680
- Testing
- Blood Draw
- Where
- Canada
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Blood Cancer, Multiple Myeloma
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Mixed chimerism transplantation is an approach to allogeneic transplants that attempts to decrease regimen-related toxicity by using non-myeloablative preparatory regimens; establish mixed chimerism using low dose total body…
- Trial name
- NCT00185614
- Testing
- Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Wen-Kai Weng
Anosmia, COVID-19
Effectiveness and Safety of Platelet Rich Plasma (PRP) on Persistent Olfactory Dysfunction Related to COVID-19
Olfactory dysfunction (OD) is a well know symptom of coronavirus disease 2019 (COVID-19), accounting for 48 to 85% of patients. In 1 to 10% of cases, patients develop a chronic olfactory dysfunction (COD,) lasting more than 6…
- Trial name
- NCT05226546
- Testing
- Platelet rich plasma (PRP), olfactory training
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Purpura, Thrombotic Thrombocytopenic, Hemolytic Uremic Syndrome
The Plasma Large-Volume Exchange RCT
Thrombotic thrombocytopenia purpura / hemolytic uremic syndrome (TTP/HUS) is a rare, life-threatening disorder. TTP/HUS causes multiple blood clots to form, which prevents blood from reaching the brain and kidneys.
- Trial name
- PLEX-RCT (NCT01433003)
- Testing
- Plasma Exchange
- Where
- Canada
- Sponsor
- London Health Sciences Centre
Chronic Low Back Pain, Sacroiliitis
Effectiveness of Ultrasound Guided Platelet Rich Plasma Injections in the Sacroiliac Joint
This prospective study will be quantitatively analyzing the effectiveness of platelet-rich-plasma (PRP) injections into the sacroiliac (SI) joint in relieving sacroiliitis and low back pain originating from the SI joint.
- Conditions
- Chronic Low Back Pain, Sacroiliitis, Sacroiliac; Backache, Platelet Rich Plasma
- Trial name
- NCT03122119
- Testing
- Platelet Rich Plasma Joint Injection
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Star Spine and Sport
Multiple Myeloma
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
Bortezomib-based triple-drug combination has greatly improved the response rate of multiple myeloma patients. Bortezomib,doxorubicin,and dexamethasone (PAD) is commonly used in clinical practice.Recent studies have found that…
- Trial name
- NCT02362165
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Planter Fasciitis
Comparison of Platelet-Rich Plasma and Prolotherapy for Plantar Fasciitis
This randomized controlled trial evaluates the comparative effectiveness of platelet-rich plasma (PRP) therapy and prolotherapy in patients with plantar fasciitis.
- Trial name
- NCT07480967
- Testing
- platelet-rich plasma injection, Prolotherapy with 25% Dextrose
- Where
- Bangladesh
- Volunteers
- 68 people
- Sponsor
- Bangladesh Medical University
Multiple Myeloma
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).
- Trial name
- NCT05271630
- Testing
- Autologous Stem Cell Transplant, Immunomodulatory Agent, Proteasome Inhibitor
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Intraepithelial Neoplasia Grade 2
Evaluation of Low-thermal Argon Plasma Devitalization for the Treatment of CIN 2 Versus Standard of Active Surveillance
The study aims to show that treatment with LtAPD works better than a sham treatment or simply monitoring the condition closely without active treatment ("active surveillance"), in achieving complete healing of a tissue…
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Intraepithelial Neoplasia Grade 2, CIN2
- Trial name
- CINPLASTA (NCT07730645)
- Testing
- Treatment with low-thermal argon plasma devitalization
- Where
- Germany
- Volunteers
- 264 people
- Sponsor
- University Hospital Tuebingen
Melasma
Efficacy of Intralesional PRP +/- Topical Silymarin in the Treatment of Melasma
Melasma is an acquired disorder of melanogenesis leading to hyperpigmentation and manifested by symmetrical brown to gray-black macules and patches with serrated irregular edges .
- Trial name
- NCT05626881
- Testing
- PRP, sylimarin cream
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Thrombotic Thrombocytopenic Purpura
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that causes blood clots to form in blood vessels. The main treatment for TTP is plasma exchange, in which affected patients receive transfusions of plasma, the liquid…
- Trial name
- STAR (NCT00799773)
- Testing
- Rituximab, Plasma exchange, Corticosteroids
- Where
- 23 sites in United States
- Volunteers
- 3 people
- Sponsor
- Carelon Research
Waldenström Macroglobulinemia
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
This is a multicenter expanded access study of zanubrutinib monotherapy for participants with B-cell malignancies who are ineligible to enroll into any available zanubrutinib clinical trials
- Trial name
- NCT04052854
- Testing
- Zanubrutinib
- Where
- 10 sites in United States
- Sponsor
- BeiGene
HIV Infection
Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults
This is a pilot study designed to determine a dose and schedule of Tucaresol that can be administered to HIV-1 infected subjects on HAART (highly active antiretroviral therapy) with viral suppression without occurrence of…
- Trial name
- NCT00343941
- Testing
- Tucaresol tablets 25 mg
- Where
- 7 sites in Italy
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and total marrow irradiation before a donor…
- Conditions
- Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
- Trial name
- NCT01163357
- Testing
- bortezomib, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center